nach oben

Erschienen in:

01.09.2003 | Original Article

Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemia

verfasst von: Francis J. Giles, Gary Guangping Shi, Jorge E. Cortes, Deborah Thomas, Anna R. Keating, Hagop M. Kantarjian, Michael J. Keating, Susan M. O'Brien

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 3/2003

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Amifostine is an organic thiophosphate that may selectively protect normal tissues from the toxicities of chemotherapy. The combination of fludarabine and cyclophosphamide (FC) is highly active in patients with chronic lymphocytic leukemia (CLL). Infection is a serious toxicity of the FC regimen.

Methods

Amifostine was added to the FC regimen in a phase II study of 46 patients with CLL. Patients received FCA (fludarabine 30 mg/m² i.v. daily for 3 days, cyclophosphamide 300 mg/m² i.v. daily for 3 days, and amifostine 500 mg i.v. over 15 min daily for 3 days starting 30 min before cyclophosphamide) at intervals of 4–6 weeks for a maximum of six courses.

Results

Patients receiving FCA had equivalent rates of sepsis, early death, objective response and survival to those observed in a prior series of 78 patients treated with FC. Amifostine-associated toxicities included nausea, vomiting, and hypotension.

Conclusion

The study amifostine regimen did not reduce the toxicity or activity of the FC regimen in patients with CLL.

Keating MJ, O'Brien S, Lerner S, Koller C, Beran M, Robertson LE, Freireich EJ, Estey E, Kantarjian H (1998) Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 92:1165PubMed

Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd L, Hines J, Threatte GA, Larson RA, Cheson BD, Schiffer CA (2000) Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 343:1750PubMed

Robak T (2002) The role of nucleoside analogues in the treatment of chronic lymphocytic leukemia—lessons learned from prospective randomized trials. Leuk Lymphoma 43:537PubMed

Leporrier M, Chevret S, Cazin B, Boudjerra N, Feugier P, Desablens B, Rapp MJ, Jaubert J, Autrand C, Divine M, Dreyfus B, Maloum K, Travade P, Dighiero G, Binet JL, Chastang C (2001) Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 98:2319CrossRefPubMed

Mauro FR, Foa R, Meloni G, Gentile M, Giammartini E, Giannarelli D, De Propris MS, Rapanotti MC, de Fabritiis P, Mandelli F (2002) Fludarabine, ara-C, novantrone and dexamethasone (FAND) in previously treated chronic lymphocytic leukemia patients. Haematologica 87:926PubMed

Hallek M, Schmitt B, Wilhelm M, Busch R, Krober A, Fostitsch HP, Sezer O, Herold M, Knauf W, Wendtner CM, Kuse R, Freund M, Franke A, Schriever F, Nerl C, Dohner H, Thiel E, Hiddemann W, Brittinger G, Emmerich B (2001) Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group. Br J Haematol 114:342PubMed

Schmitt B, Wendtner CM, Bergmann M, Busch R, Franke A, Pasold R, Schlag R, Hopfinger G, Hiddemann W, Emmerich B, Hallek M (2002) Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia. Clin Lymphoma 3:26PubMed

O'Brien SM, Kantarjian HM, Cortes J, Beran M, Koller CA, Giles FJ, Lerner S, Keating M (2001) Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol 19:1414PubMed

Giles FJ, O'Brien SM, Santini V, Gandhi V, Plunkett W, Seymour JF, Robertson LE, Kantarjian HM, Keating MJ (1999) Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: a phase II study. Leuk Lymphoma 36:57PubMed

10.

Tsimberidou AM, O'Brien SM, Cortes JE, Faderl S, Andreeff M, Kantarjian HM, Keating MJ, Giles FJ (2002) Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders. Leuk Lymphoma 43:767CrossRefPubMed

11.

Morrison VA, Rai KR, Peterson BL, Kolitz JE, Elias L, Appelbaum FR, Hines JD, Shepherd L, Martell RE, Larson RA, Schiffer CA (2001) Impact of therapy with chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011. J Clin Oncol 19:3611PubMed

12.

Robak T, Kasznicki M (2002) Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia, Leukemia 16:1015

13.

Marotta G, Bigazzi C, Lenoci M, Tozzi M, Bocchia M, Lauria F (2000) Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy. Haematologica 85:1268PubMed

14.

Flinn IW, Byrd JC, Morrison C, Jamison J, Diehl LF, Murphy T, Piantadosi S, Seifter E, Ambinder RF, Vogelsang G, Grever MR (2000) Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. Blood 96:71PubMed

15.

Bellosillo B, Villamor N, Colomer D, Pons G, Montserrat E, Gil J (1999) In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia. Blood 94:2836PubMed

16.

Zaja F, Rogato A, Russo D, Marin L, Silvestri F, Baccarani M (1997) Combined therapy with fludarabine and cyclophosphamide in relapsed/resistant patients with B-cell chronic lymphocytic leukaemia and non-Hodgkin's lymphomas. Eur J Haematol 59:327PubMed

17.

Frewin R, Turner D, Tighe M, Davies S, Rule S, Johnson S (1999) Combination therapy with fludarabine and cyclophosphamide as salvage treatment in lymphoproliferative disorders. Br J Haematol 104:612CrossRefPubMed

18.

Binet JL (1993) Treatment of chronic lymphocytic leukaemia. French Co-operative Group on CLL. Baillieres Clin Haematol 6:867PubMed

19.

Yamauchi T, Nowak BJ, Keating MJ, Plunkett W (2001) DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res 7:3580PubMed

20.

Santini V, Giles FJ (1999) The potential of amifostine: from cytoprotectant to therapeutic agent. Haematologica 84:1035PubMed

21.

Sriswasdi C, Jootar S, Giles FJ (2000) Amifostine and hematologic effects. J Med Assoc Thai 83:374PubMed

22.

van der Vijgh WJ, Peters GJ (1994) Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (Ethyol): preclinical aspects. Semin Oncol 21:2

23.

Alberts DS (1999) Protection by amifostine of cyclophosphamide-induced myelosuppression. Semin Oncol 26:37PubMed

24.

Capizzi RL (1999) The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine. Semin Oncol 26:3

25.

Santini V (2001) Amifostine: chemotherapeutic and radiotherapeutic protective effects. Expert Opin Pharmacother 2:479PubMed

26.

Anaissie EJ, Kontoyiannis DP, O'Brien S, Kantarjian H, Robertson L, Lerner S, Keating MJ (1998) Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med 129:559PubMed

27.

O'Brien S, Kantarjian H, Beran M, Koller C, Talpaz M, Lerner S, Keating MJ (1997) Fludarabine and granulocyte colony-stimulating factor (G-CSF) in patients with chronic lymphocytic leukemia. Leukemia 11:1631CrossRefPubMed

28.

Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S, Rai KR (1996) National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 87:4990PubMed

29.

Spath-Schwalbe E, Lange C, Genvresse I, Kruger L, Eucker J, Schweigert M, Sezer O, Budach V, Possinger K (2002) Influence of amifostine on toxicity of CHOP in elderly patients with aggressive non-Hodgkin's lymphoma—a phase II study. Anticancer Drugs 13:395CrossRefPubMed

30.

Ghielmini M, Van der Bosch S, Bosshard M, Pampallona S, Gabutti L, Egger HP, Kiess M, Cavalli F, Sessa C (2001) Phase I-II study of escalating doses of amifostine combined with high-dose cyclophosphamide. Cancer Chemother Pharmacol 47:532CrossRefPubMed

31.

Senzer N (2002) A phase III randomized evaluation of amifostine in stage IIIA/IIIB non-small cell lung cancer patients receiving concurrent carboplatin, paclitaxel, and radiation therapy followed by gemcitabine and cisplatin intensification: preliminary findings. Semin Oncol 29:38CrossRef

32.

Haigentz M Jr, Kim M, Sorich J, Lee J, Hochster H, Macapinlac M, Mirchandani D, Sewak S, Pavlick A, Volm M, Hamilton A, Muggia FM (2003) Phase I study of amifostine as a cytoprotector of the gemcitabine/cisplatin combination in patients with advanced solid malignancies. Anticancer Drugs 14:321CrossRefPubMed

33.

Souid AK, Dubowy RL, Blaney SM, Hershon L, Sullivan J, McLeod WD Bernstein ML (2003) Phase I clinical and pharmacologic study of weekly cisplatin and irinotecan combined with amifostine for refractory solid tumors. Clin Cancer Res 9:703PubMed

34.

Garcia-Manero G, Faderl S, Giles F, Thomas D, Cortes J, O'Brien S, Davis J, Kantarjian HM, Estey E (2002) A phase I study of idarubicin dose escalation with amifostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes. Haematologica 87:804PubMed

35.

Grdina DJ, Hunter N, Kataoka Y, Murley JS, Milas L (1999) Chemopreventive doses of amifostine confer no cytoprotection to tumor nodules growing in the lungs of mice treated with cyclophosphamide, Semin Oncol 26:22

36.

Shapiro JD, Rothenberg ML, Sarosy GA, Steinberg SM, Adamo DO, Reed E, Ozols RF, Kohn EC (1998) Dose intensive combination platinum and cyclophosphamide in the treatment of patients with advanced untreated epithelial ovarian cancer. Cancer 83:1980CrossRefPubMed

37.

Kemp G, Rose P, Lurain J, Berman M, Manetta A, Roullet B, Homesley H, Belpomme D, Glick J (1996) Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 14:2101PubMed

38.

Glick JH, Glover DJ, Weiler C, Blumberg A, Nelson D, Yuhas JM, Kligerman M (1982) Phase I clinical trials of WR-2721 with alkylating agent chemotherapy. Int J Radiat Oncol Biol Phys 8:575PubMed

39.

Glick JH, Glover D, Weiler C, Norfleet L, Yuhas J, Kligerman MM (1984) Phase I controlled trials of WR-2721 and cyclophosphamide. Int J Radiat Oncol Biol Phys 10:1777PubMed

40.

Morrison VA (1998) The infectious complications of chronic lymphocytic leukemia. Semin Oncol 25:98

41.

Samonis G, Kontoyiannis DP (2001) Infectious complications of purine analog therapy. Curr Opin Infect Dis 14:409PubMed

42.

O'Brien S, Kantarjian H, Beran M, Smith T, Koller C, Estey E, Robertson LE, Lerner S, Keating M (1993) Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood 82:1695PubMed

43.

Anaissie E, Kontoyiannis DP, Kantarjian H, Elting L, Robertson LE, Keating M (1992) Listeriosis in patients with chronic lymphocytic leukemia who were treated with fludarabine and prednisone. Ann Intern Med 117:466PubMed

44.

Byrd JC, Hargis JB, Kester KE, Hospenthal DR, Knutson SW, Diehl LF (1995) Opportunistic pulmonary infections with fludarabine in previously treated patients with low-grade lymphoid malignancies: a role for Pneumocystis carinii pneumonia prophylaxis. Am J Hematol 49:135PubMed

45.

Schiller JH, Storer B, Berlin J, Wittenkeller J, Larson M, Pharo L, Berry W (1996) Amifostine, cisplatin, and vinblastine in metastatic non-small-cell lung cancer: a report of high response rates and prolonged survival. J Clin Oncol 14:1913PubMed

46.

Gelmon K, Eisenhauer E, Bryce C, Tolcher A, Mayer L, Tomlinson E, Zee B, Blackstein M, Tomiak E, Yau J, Batist G, Fisher B, Iglesias J (1999) Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer. J Clin Oncol 17:3038PubMed

47.

Hartmann JT, Fels LM, Knop S, Stolt H, Kanz L, Bokemeyer C (2000) A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumors. Invest New Drugs 18:281CrossRefPubMed

48.

Schuchter LM (1996) Guidelines for the administration of amifostine. Semin Oncol 23:40

49.

Schuchter LM, Hensley ML, Meropol NJ, Winer EP (2002) 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 20:2895CrossRefPubMed

50.

Hofmann WK, Seipelt G, Ottmann OG, Kalina U, Koschmieder S, Brucher J, Frickhofen N, Klausmann M, Mitrou PS, Hoelzer D (2000) Effect of treatment with amifostine used as a single agent in patients with refractory anemia on clinical outcome and serum tumor necrosis factor alpha levels. Ann Hematol 79:255CrossRefPubMed

51.

Antonadou D (2002) Radiotherapy or chemotherapy followed by radiotherapy with or without amifostine in locally advanced lung cancer. Semin Radiat Oncol 12:50CrossRefPubMed

52.

Budd GT, Ganapathi R, Bauer L, Murthy S, Adelstein D, Weick J, Gibson V, McLain D, Sergi J, Bukowski RM (1993) Phase I study of WR-2721 and carboplatin. Eur J Cancer 8:1122

53.

Hartmann JT, Knop S, Fels LM, van Vangerow A, Stolte H, Kanz L, Bokemeyer C (2000) The use of reduced doses of amifostine to ameliorate nephrotoxicity of cisplatin/ifosfamide-based chemotherapy in patients with solid tumors. Anticancer Drugs 11:1CrossRefPubMed

54.

Bukowski RM (1996) Amifostine (Ethyol): dosing, administration and patient management guidelines. Eur J Cancer 32A:S46CrossRefPubMed

55.

Culy CR, Spencer CM (2001) Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome. Drugs 61:641PubMed

56.

Lindemann K (1998) Administration of the cytoprotectant amifostine. Clin J Oncol Nurs 2:101PubMed

57.

Koukourakis MI, Romanidis K, Froudarakis M, Kyrgias G, Koukourakis GV, Retalis G, Bahlitzanakis N (2002) Concurrent administration of docetaxel and Stealth liposomal doxorubicin with radiotherapy in non-small cell lung cancer: excellent tolerance using subcutaneous amifostine for cytoprotection. Br J Cancer 87:385

58.

Giles FJ (1998) Monocyte-macrophages, granulocyte-macrophage colony-stimulating factor, and prolonged survival among patients with acute myeloid leukemia and stem cell transplants. Clin Infect Dis 26:1282PubMed

Titel: Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemia
verfasst von: Francis J. Giles
Gary Guangping Shi
Jorge E. Cortes
Deborah Thomas
Anna R. Keating
Hagop M. Kantarjian
Michael J. Keating
Susan M. O'Brien
Publikationsdatum: 01.09.2003
Verlag: Springer-Verlag
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 3/2003
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-003-0654-4

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemia